Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting

Initial Phase II JASPIS-01 results showed clinical activity and a manageable safety profile for dapolsertib monotherapy in heavily pretreated patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma; patients had a median of four prior therapy lines, with 53% previously receiving CAR-T and 60% CD3×CD20 bispecific antibodies. The results are preliminary, and dapolsertib remains investigational; the data will be presented at ASH on December 13, 2026.

Analysis

The key equity question is value capture, not biological novelty: Menarini holds global development and commercial rights and funds R&D, so dapolsertib is an externally financed asset for Ryvu, but the announcement does not disclose the milestones, royalties, or other economics that translate clinical success into RVU value. Treat the read-through as pipeline de-risking, not a near-term revenue revision.

The current evidence is not yet investable efficacy: the release omits response rate, response duration, patient count, follow-up, and granular adverse-event data. Activity in heavily treated patients is hypothesis-generating; it does not establish durable benefit against available salvage options such as antibody-drug conjugates or other targeted and cellular approaches. The combination arm with glofitamab may ultimately be more commercially relevant, but it is a separate question from monotherapy activity in a post-treatment population.

Near term, the December ASH presentation is a defined volatility catalyst, with potential for the market to price qualitative language ahead of interpretable clinical detail. Over 1–3 months, focus on the actual poster and any subsequent enrollment or cohort updates. Over 6–18 months, durable response and tolerability—not kinase-mechanism novelty—would determine whether this becomes a credible niche option. A weak or short-lived response signal, dose-limiting toxicity, or no progress in the combination cohort would reverse the optimism. The contrarian point: substantial unmet need can make a small early signal sound more commercially meaningful than it is, while RVU’s upside may be capped or deferred by undisclosed license economics.

Key Decisions for Investors

• RVU: do not chase the announcement on the qualitative signal alone. Treat it as a watch catalyst into the December 13 ASH poster; consider adding only after reviewing ORR, duration of response, follow-up, patient count, and grade 3+ toxicity.
• Before assigning meaningful value to dapolsertib in an RVU model, verify the license’s royalty and milestone schedule and whether any additional development obligations fall on Ryvu. Menarini-funded trials reduce direct cash-burn exposure, but do not establish material economics for RVU.
• Monitor the glofitamab combination separately from monotherapy. A credible combination signal could improve differentiation; absent that, established salvage modalities and clinical-trial alternatives constrain the addressable post-CAR-T/post-bispecific niche.
• Falsification watch: de-rate the clinical option if the poster shows low or non-durable responses, meaningful dose-limiting toxicity, or subsequent updates fail to support the combination strategy. No directional trade is warranted without the clinical detail and contract economics.